Back to company

NORDIC PHARMACEUTICALS ApS: Financial statements 2015

CVR: 27430015

NORDIC PHARMACEUTICALS ApS (CVR 27430015) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 1,295,706 and a net result of DKK 281,651 compared with DKK 151,604 the year before. That is an increase of 44.2% compared with the year before. Equity amounted to DKK 1,043,880. The solvency ratio was 29.1%.

Gross Profit
1,295,706 kr.
Profit/Loss
281,651 kr.
Equity
1,043,880 kr.
Total Assets
3,591,242 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2015-1.3 mio.282 t.1 mio.-
2014-899 t.152 t.762 t.-
2013-808 t.190 t.611 t.-
2012-959 t.421 t.614 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2015

Lars Bo Holløse Nielsen registered as owner of NORDIC PHARMACEUTICALS ApSNov 17, 2015

As of November 17, 2015, Lars Bo Holløse Nielsen is registered as an owner of NORDIC PHARMACEUTICALS ApS with an ownership share of 50%.

Kea Ok Junge registered as owner of NORDIC PHARMACEUTICALS ApSNov 17, 2015

As of November 17, 2015, Kea Ok Junge is registered as an owner of NORDIC PHARMACEUTICALS ApS with an ownership share of 50%.

NORDIC PHARMACEUTICALS ApS: The 2014 annual report is outJun 28, 2015

NORDIC PHARMACEUTICALS ApS has published its annual report for 2014. Gross profit came to DKK 898,701, and the net result was DKK 151,604.

About NORDIC PHARMACEUTICALS ApS

NORDIC PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 2003. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The management consists of Lars Bo Holløse Nielsen. The company is owned by Lars Bo Holløse Nielsen and Kea Ok Junge. The company has 3 employees. In 2024, the company reported a gross profit of DKK -2,243,265 and a net result of DKK -2,664,416 compared with DKK 9,351 the year before. Equity amounted to DKK -1,152,541.